Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an inhaler for treating infections caused by non-tuberculous mycobacteria. The company notes that there's currently no FDA-approved treatment for this particular NTM lung infection.
Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an...
From other sites
at CNBC.com (Jun 18, 2014)
at CNBC.com (Mar 26, 2014)
at CNBC.com (Oct 27, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs